PMID- 32311990
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20200905
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 16
DP  - 2020 Apr
TI  - A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment 
      effect for chronic obstructive pulmonary disease: A meta-analysis.
PG  - e19789
LID - 10.1097/MD.0000000000019789 [doi]
LID - e19789
AB  - BACKGROUND: Combinations of long-acting bronchodilators with different mechanisms 
      of action are recommended to improve prognosis and reduce risk of adverse events 
      of chronic obstructive pulmonary disease (COPD). It is unclear whether the new 
      combination therapy with long-acting muscarinic antagonist (LAMA) tiotropium 
      (TIO) and long acting beta-agonists (LABA) olodaterol (OLO) was superior to 
      tiotropium alone. METHODS: We measured the efficacy of the TIO/OLO combination 
      vsTIO alone for COPD patients based on electronic databases up to February 2019. 
      After rigorous quality review, data was extracted from eligible trials. All the 
      main outcomes were pooled analysis using RevMan software. RESULTS: A total of 6 
      randomized controlled trials (RCTs) were identified. The pooled results of our 
      meta-analysis demonstrated that FEV1 [MD = 0.03, 95% CI (-0.01,0.07), P = .18], 
      FVC [MD = -0.03, 95%CI (-0.06,0.00), P = .09] and FEV1%pred [MD = 0.35, 95%CI 
      (-0.30, 0.99), P = .29] all showed no significant difference between the 2 
      groups. The overall incidence of adverse effects (AEs) [OR = 1.01,95%CI 
      (0.93,1.09), P = .87] and serious AEs [OR = 1.04,95% CI (0.82, 1.32), P = .72] in 
      the combination group was similar to that of the TIO alone group, without 
      statistical significance. CONCLUSION: These studies reported that the TIO/OLO 
      combination did not show superior effects than tiotropium alone for COPD. 
      Additionally, both therapies were well tolerated.
FAU - He, Jie
AU  - He J
AD  - Department of Respiratory and Critical Care Medicine, China-Japan Friendship 
      Hospital, Beijing, China.
FAU - Lin, Jiang-Tao
AU  - Lin JT
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Retracted Publication
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Benzoxazines)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (tiotropium-olodaterol)
RN  - XX112XZP0J (Tiotropium Bromide)
SB  - IM
RIN - Medicine (Baltimore). 2020 Sep 18;99(38):e22420. PMID: 32957422
MH  - Benzoxazines/*therapeutic use
MH  - Bronchodilator Agents/*therapeutic use
MH  - Drug Combinations
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy
MH  - Tiotropium Bromide/*therapeutic use
MH  - Vital Capacity
PMC - PMC7440302
COIS- The authors have no funding and conflicts of interests to disclose.
EDAT- 2020/04/22 06:00
MHDA- 2020/04/25 06:00
PMCR- 2020/04/17
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
PHST- 2020/04/17 00:00 [pmc-release]
AID - 00005792-202004170-00074 [pii]
AID - MD-D-19-09210 [pii]
AID - 10.1097/MD.0000000000019789 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(16):e19789. doi: 10.1097/MD.0000000000019789.